Kennedy Capital Management LLC Decreases Stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Kennedy Capital Management LLC reduced its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 24.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 55,748 shares of the specialty pharmaceutical company’s stock after selling 18,061 shares during the period. Kennedy Capital Management LLC’s holdings in Eagle Pharmaceuticals were worth $292,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Eagle Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 2,630 shares during the period. Headlands Technologies LLC raised its position in Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 2,861 shares during the period. Tower Research Capital LLC TRC raised its position in Eagle Pharmaceuticals by 623.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 5,896 shares during the period. DGS Capital Management LLC purchased a new stake in Eagle Pharmaceuticals during the fourth quarter valued at approximately $60,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Eagle Pharmaceuticals during the first quarter valued at approximately $83,000. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a research note on Thursday. They set a “hold” rating on the stock.

Eagle Pharmaceuticals Stock Performance

EGRX opened at $4.78 on Friday. The stock has a market cap of $62.08 million, a price-to-earnings ratio of 4.05 and a beta of 0.51. The stock’s 50 day moving average price is $4.77 and its 200-day moving average price is $5.02. Eagle Pharmaceuticals, Inc. has a one year low of $3.21 and a one year high of $23.52.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.